Bioinformatics analysis reveals the potential target of rosiglitazone as an antiangiogenic agent for breast cancer therapy
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2730-6844
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Bioinformatics analysis reveals the potential target of rosiglitazone as an antiangiogenic agent for breast cancer therapy ; volume:23 ; number:1 ; day:16 ; month:9 ; year:2022 ; pages:1-17 ; date:12.2022
BMC genomic data ; 23, Heft 1 (16.9.2022), 1-17, 12.2022
- Creator
-
Hermawan, Adam
Putri, Herwandhani
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12863-022-01086-2
- URN
-
urn:nbn:de:101:1-2022120309345158885940
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:32 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Hermawan, Adam
- Putri, Herwandhani
- SpringerLink (Online service)
Other Objects (12)
Antiangiogenic therapy
Neoadjuvant antiangiogenic therapy reveals contrasts in primary and metastatic tumor efficacy
A Combined Proteomics and Bioinformatics Approach Reveals Novel Signaling Pathways and Molecular Targets After Intracerebral Hemorrhage
Metabolic and hypoxic adaptation to anti‐angiogenic therapy: a target for induced essentiality
UPARANT is an effective antiangiogenic agent in a mouse model of rubeosis iridis
Antiangiogenic effects of oridonin
Bioinformatics analysis of Brucellavaccines and vaccine targets using VIOLIN
The targets of aspirin in bladder cancer: bioinformatics analysis
Characterization of the myxobacterial compound Chondramide as novel anti-angiogenic and anti-metastatic agent
Characterization of the myxobacterial compound Chondramide as novel anti-angiogenic and anti-metastatic agent
Vascular disruptive agent OXi4503 and anti-angiogenic agent Sunitinib combination treatment prolong survival of mice with CRC liver metastasis
Antiangiogenic therapy in breast cancer
Antiangiogenic therapy
Neoadjuvant antiangiogenic therapy reveals contrasts in primary and metastatic tumor efficacy
A Combined Proteomics and Bioinformatics Approach Reveals Novel Signaling Pathways and Molecular Targets After Intracerebral Hemorrhage
Metabolic and hypoxic adaptation to anti‐angiogenic therapy: a target for induced essentiality
UPARANT is an effective antiangiogenic agent in a mouse model of rubeosis iridis
Antiangiogenic effects of oridonin
Bioinformatics analysis of Brucellavaccines and vaccine targets using VIOLIN
The targets of aspirin in bladder cancer: bioinformatics analysis
Characterization of the myxobacterial compound Chondramide as novel anti-angiogenic and anti-metastatic agent
Characterization of the myxobacterial compound Chondramide as novel anti-angiogenic and anti-metastatic agent
Vascular disruptive agent OXi4503 and anti-angiogenic agent Sunitinib combination treatment prolong survival of mice with CRC liver metastasis
Antiangiogenic therapy in breast cancer
Antiangiogenic therapy
Neoadjuvant antiangiogenic therapy reveals contrasts in primary and metastatic tumor efficacy
A Combined Proteomics and Bioinformatics Approach Reveals Novel Signaling Pathways and Molecular Targets After Intracerebral Hemorrhage
Metabolic and hypoxic adaptation to anti‐angiogenic therapy: a target for induced essentiality
UPARANT is an effective antiangiogenic agent in a mouse model of rubeosis iridis
Antiangiogenic effects of oridonin
Bioinformatics analysis of Brucellavaccines and vaccine targets using VIOLIN
The targets of aspirin in bladder cancer: bioinformatics analysis
Characterization of the myxobacterial compound Chondramide as novel anti-angiogenic and anti-metastatic agent
Characterization of the myxobacterial compound Chondramide as novel anti-angiogenic and anti-metastatic agent
Vascular disruptive agent OXi4503 and anti-angiogenic agent Sunitinib combination treatment prolong survival of mice with CRC liver metastasis